<DOC>
	<DOCNO>NCT00576173</DOCNO>
	<brief_summary>The purpose study evaluate analgesic effectiveness safety 37.5mg Tramadol hydrochloride/325mg Acetaminophen treatment breakthrough pain cancer patient .</brief_summary>
	<brief_title>An Open Label Study Evaluate Safety , Tolerability Clinical Utility ULTRACETÂ® ( 37.5mg Tramadol Hydrochloride/325mg Acetaminophen ) Treatment Breakthrough Pain Cancer Patients</brief_title>
	<detailed_description>The combination tramadol HCI/acetaminophen provide rapid onset action compare tramadol HCI alone long duration action acetaminophen alone . Therefore , combination tramadol acetaminophen may effective treatment cancer pain well allow lower cumulative daily dosage medication used.This open-label study . Patients receive one-dose treatment 37.5mg Tramadol/325mg Acetaminophen tablets.This study design investigate follow hypothesis : Tramadol hydrochloride/acetaminophen effective treatment breakthrough pain cancer patients.The patient complete basic question side effect visit entry , 10 , 30 min , 1h . The patient receive one dose treatment Tramadol hydrochloride/Acetaminophen oral tablet throughout study . The number oral tablet give depend total daily dose around-clock medication . If around-clock medication Tramadol &lt; =400mg codeine &lt; =300mg morphine &lt; 60mg , breakthrough pain medication 1 tablet . If around-clock medication morphine 60-120mg Fentanyl &gt; =25 ug/hr , breakthrough pain medication 2 tablet .</detailed_description>
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Tramadol</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Patients histologically , radiologically haematologically confirmed malignancy whose pain judge investigator cause malignancy Patients must stable daily dose weak opioids strong opioids least 72 hour prior start study must remain dosage duration study Patients must VAS ( Visual analog scale ) &gt; =40mm Patients take either morphine daily dose 120mg Fentanyl daily dose 50ug/hr Patients significant abnormality hepatic renal function would , opinion investigator , prevent patient involvement study Patients significant clinical abnormality CNS , respiratory cardiovascular function , investigator judgement prevents participation study Patients take antidepressant antiepileptic drug , sedative hypnotic , selective serotonin reuptake inhibitor , shortacting analgesic , topical medication anesthetic and/or muscle relaxant take Tramadol/Acetaminophen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Cancer pain</keyword>
	<keyword>Breakthrough pain</keyword>
	<keyword>acetaminophen</keyword>
	<keyword>tramadol hydrochloride</keyword>
	<keyword>Ultracet</keyword>
</DOC>